TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06155903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Spinal Anesthesia
Description: Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blocks
Description: In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesiological mixtures (Spinal anesthesia)
Description: The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesiological mixtures (Peripheral nerve block)
Description: The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
Study: NCT06013384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound Pulsation
Description: Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.

Intervention type: DEVICE
Group type: OTHER
Intervention: Low-Intensity Focused Ultrasound Pulsation
Description: Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Low-Intensity Focused Ultrasound Pulsation
Description: Sham low-intensity focused ultrasound pulsation will be given.
Study: NCT06335303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1819479
Description: Placebo matching BI 1819479
Study: NCT06548490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide will be provided using an injection pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be a dry needle stick; no substances will be injected
Study: NCT04814082

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)
Description: Medial Pivot Knee System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)
Description: Single Radius Design Total Knee System
Study: NCT05538663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin
Description: intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
Study: NCT05228197

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy & Imaging
Description: H\&E stained prostate biopsy slides from standard of care treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy & Imaging
Description: H\&E stained prostate biopsy slides from standard of care treatment
Study: NCT06241573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study: NCT05223816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG161
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG161
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: immunotherapy treatment
Study: NCT06043648

Intervention type: DEVICE
Intervention: Endotracheal tube cuff pressure monitoring
Description: The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
Study: NCT06414603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Prospera™ Test
Description: The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory.
Study: NCT06302049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: esomeprazole 20 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT05388656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release
Description: 0.1 mg/day transdermal patch administered for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release
Description: 0.1 mg/day transdermal patch administered for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Estradiol-matched placebo patch administered for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Estradiol-matched placebo patch administered for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg
Description: 200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg
Description: 200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study
Study: NCT06467747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music group: wear earphones to listen to music and receive standardized anesthesia protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mute
Description: Mute group: wear earphones without music and receive standardized anesthesia protocol
Study: NCT06439277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05339685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M02D1
Description: Administration by intravenous infusion
Study: NCT06538259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)-anodal group
Description: 2mA/20mins/session; 2sessions/day,5days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)-sham group
Description: 0mA/20mins/session; 2sessions/day,5days
Study: NCT06500429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101
Description: Drug: Including placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Including placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.5 or 1 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.5 or 1 mg
Study: NCT04844606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV
Study: NCT05901831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Dose A, Dose B, oral
Study: NCT06477705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAM
Description: Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
Study: NCT04849624

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study and involved no intervention

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study and involved no intervention
Study: NCT05003869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scar tissue is removed
Description: The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
Study: NCT05404711

Intervention type: DEVICE
Group type: OTHER
Intervention: CGM
Description: Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
Study: NCT06137820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cetilar® (topical cream)
Description: Topical cream twice daily for 30 days. An average amount of 5 g per day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cetilar Placebo
Description: Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
Study: NCT06371274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
Study: NCT06608407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP group
Description: After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
Study: NCT06609408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature and Game Based Activities
Description: Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
Study: NCT06611566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided aerobic exercise
Description: The intervention was 5 minutes of VR-guided aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided aerobic exercise
Description: The intervention was 5 minutes of VR-guided aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness exercise
Description: The intervention was 5 minutes of VR-guided mindfulness exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-guided mindfulness exercise
Description: The intervention was 5 minutes of VR-guided mindfulness exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided aerobic exercises
Description: The intervention was 5 minutes of TV-guided aerobic exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided aerobic exercises
Description: The intervention was 5 minutes of TV-guided aerobic exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided mindfulness exercises
Description: The intervention was 5 minutes of VR-guided mindfulness exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV-guided mindfulness exercises
Description: The intervention was 5 minutes of VR-guided mindfulness exercises
Study: NCT06612580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-AAZTA-NI-093
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT06612749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine including manual and/or mind-body treatments
Description: Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
Study: NCT06613009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3009
Description: Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
Study: NCT06613282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Transcranial Magnetic Stimulation
Description: * Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory and visual stimulation
Description: * Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx.
Study: NCT06612372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-day-6° head-down bed rest
Description: Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
Study: NCT06613178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
Study: NCT06611488

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No Intervention as the study is bservational Cohort
Study: NCT05901831

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05834127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercises
Description: Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose
Study: NCT04833062

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.

Intervention type: OTHER
Intervention: Survey
Description: The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI.

Intervention type: OTHER
Intervention: Survey
Description: The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI.
Study: NCT04776577

Intervention type: DEVICE
Group type: OTHER
Intervention: Wirecath@ and Abbott PressureWire® (20 patients)
Description: Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®

Intervention type: DEVICE
Group type: OTHER
Intervention: Wirecath® (20 patients)
Description: FFR measurement with Wirecath® only

Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary flow reserve
Description: Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
Study: NCT06553482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FatMAx training intervention
Description: FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FatMax and physical endurance exercise intervention
Description: FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention pf physical activity